Biopharma Companies in United Kingdom (UK)

TEK Optima Research is a leading provider of advanced imaging systems and AI-powered software solutions, based in Wimborne, Dorset, UK.

We specialize in designing and manufacturing high-performance hardware and innovative DeepInsight cell fingerprinting technology for the Biotech, Medical, and related microscopic imaging industries. Our solutions enable faster, more accurate results for researchers and clinicians.

TEK Optima Research combines cutting-edge hardware development with sophisticated data analytics and AI to deliver a complete imaging platform. We support a wide range of applications, from drug discovery to clinical diagnostics.

Founded in 2019, we’ve quickly established ourselves as a trusted partner for organizations seeking to push the boundaries of microscopic imaging. We currently employ a team of 5 dedicated professionals, operating from our R&D office and manufacturing facility in Dorset and a secondary R&D office in Durham, NC.

Genomics is a pioneering transatlantic TechBio company based in Oxford, UK, specializing in **genomic prevention** and transforming healthcare through the power of genomics.

We leverage large-scale genetic information to provide accurate, personalized risk estimates for common diseases and cancers, enabling early interventions and tailored screening. Our proprietary algorithms and databases link minute variations across the entire genome to biological measurements and disease outcomes, generating population-level insights for healthcare systems and individual-level risk assessments for clinicians.

Genomics partners with leading life sciences and biotech companies, including Novo Nordisk and Vertex, offering a unique approach to sustainable healthcare. Our team of over 150 experts – including world-leading genomic scientists, computational biologists, and data scientists – is dedicated to bringing subject-leading science to a global audience, ultimately transforming lives.

Bond Chemicals is a Manchester-based global supplier of fine and speciality chemicals, pharmaceutical intermediates, and raw materials for drug development.

We specialize in sourcing alternative commercial sources and custom synthesis, serving a diverse range of clients in the Life Sciences Industry, including those developing drugs across all phases of development.

Bond Chemicals distinguishes itself through its extensive worldwide network of manufacturing partners, offering a comprehensive product range from grammes to multi-tonnes, coupled with a commitment to quality assurance, competitive pricing, and expert technical support.

Founded in 2003, Bond Chemicals operates from its UK headquarters in Warrington, with additional facilities in Dublin (EU) and New Jersey (US), providing seamless supply chain solutions globally.

BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in old age is inevitable. At Causeway, we believe that physical decline in old age is not inevitable and in indeed may be reversible. To address this, we are developing a range of therapies that treat common MSK diseases that will allow us to remain fit and active into our nineties and beyond. Staying active as we get older also reduces the risk of developing osteoporosis, dementia, diabetes, obesity, cancer and cardiovascular disease. Finding a way to remain fit and active as we age isn’t just a personal imperative but also a global one. By 2050, one in four of us will be over 65 years old, the number of people age over 80 is projected to triple and retirement age to rise to 75-80 years old. As individuals and as a society, we need to find solutions to the problems of ageing. Our goal is to develop therapies that treat the most common MSK diseases, such as osteoarthritis, tendinopathy and lower back pain, re-defining what old age looks and feels like.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumours. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery and PARP inhibitors; key staff at Artios developed the drug olaparib (Lynparza ™). Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Providing predictive analytics from suspended-cells through our unbiased cytometry technology, Cytomos® Dielectric Spectroscopy: CDS™

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

VitalMeds is your trusted community pharmacy Manchester, committed to providing convenient and reliable healthcare support. Location : 802 hyde Road M18 7JD ,Manchester, England. Number :+44 01612077123 Email: info@vitalmeds.co.uk